RecruitingNot Applicable

Eluvia DES for the Patients with Femoropopliteal Artery Lesions.

China400 participantsStarted 2022-08-01

Plain-language summary

This study is a multicenter, prospective, observational study, aiming to enroll 400 patients with peripheral arterial disease in the femoral-popliteal segment implanted with Eluvia stent. Each patient was followed up for 2 years. The technical success rate, target lesion patency rate, quality of life improvement, cost of Eluvia stent implantation, and other outcomes will be analysed.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Rutherford Stage 2-5.
✓. At least 90% stenosis or occlusion of the femoropopliteal artery.
✓. Eluvia stents are used for target lesions.
✓. Agree and sign the informed consent form

Exclusion criteria

✕. Life expectancy is less than 1 year.
✕. Those with severe infection and gangrene of the limbs or those with tissue defects beyond the plane of the toes (ie major tissue loss), who may undergo major amputation even if the blood vessels are opened.
✕. Patients and their families are reluctant to join the observational study, or have difficulty in communication and are unable to assess the quality of life.
✕. Patients with in-stent restenosis of the femoral popliteal artery.
✕. Patients with acute arterial thrombosis.

What they're measuring

The change of Rutherfor classification

Timeframe: 24 months

F-TLR

Timeframe: 24 months

limb salvage rate

Timeframe: 24 months

Trial details

NCT IDNCT05522218

SponsorFirst Affiliated Hospital of Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08-01

View on ClinicalTrials.gov More Vascular Diseases trials